I
nvasive meningococcal disease (IMD), is caused by the strict human pathogen Neisseria meningitidis, which is divided into 12 different serogroups based on unique capsular polysaccharide structures on the surface of the bacteria that can be recognized by specific serogrouping antisera (53) . Further phenotypic subdivisions are based on 2 major outer membrane proteins, PorB and PorA, which contain antigens, detectable by a panel of monoclonal antibodies, corresponding to serotypes and serosubtypes, respectively (24) . Genetic analysis by multilocus sequence typing (MLST), which is based on nucleotide sequence differences in 7 housekeeping enzyme genes, allows the bacteria to be grouped into clonal groups or clonal complexes (CCs) (34) .
Most meningococcal infections are not noticed due to asymptomatic transmissions occurring between healthy individuals (carriers), but for reasons not completely understood, sometimes infections may result in serious invasive disease, with mortality rates reaching 10% or more (43) . IMD occurs globally as endemic or sporadic disease, and occasionally outbreaks or epidemics occur. Analysis of N. meningitidis isolates from sporadic disease cases or asymptomatic carriers shows that the organism is composed of a highly heterogeneous population of bacteria, while isolates recovered from outbreaks or epidemics usually belong to only a limited number of clones, so-called hypervirulent clones or lineages (10, 41) .
In Canada, the last major meningococcal epidemic occurred in the late 1930s to early 1940s and was caused by serogroup A bacteria, with a peak incidence of close to 13 cases per 100,000 population (36) . Another major event in more recent history was the identification of the serogroup C, serotype 2a, electrophoretic type (ET) 15 clone, which emerged in 1986 (2) to cause two waves of outbreaks in different provinces in Canada in 1989 to 1991 (17, 22, 28, 46, 48, 54) and again in 2000 to 2001 (40, 49, 50) . This clone also spread to the United States (29) and other parts of the world (31) .
As a result of the serogroup C meningococcal outbreaks, the province of Québec instituted two rounds of province-wide vaccination campaigns in the last 20 years. The first campaign was launched between December 1992 and March 1993 using plain tetravalent (A, C, Y, W135) or bivalent (A, C) polysaccharide vaccines (17) . The second province-wide vaccination campaign was launched in May to June 2001 using the serogroup C glycoconjugate vaccine (Menjugate; Chiron, Emeryville, CA), which was offered to all residents age 2 months to 20 years (18, 19 
MATERIALS AND METHODS
IMD cases and bacterial isolates. Since IMD is a notifiable disease, clinicians and laboratories are required to report cases to the public health authority, and laboratories are invited to submit isolates from IMD cases to the provincial public health laboratory, Laboratorie de Santé Publique du Québec (LSPQ). Only culture-confirmed IMD cases were included in this study, and age information was recorded from the specimen requisition form. When N. meningitidis was recovered from multiple specimen types, only one isolate was included for the analysis.
As most cases reported by clinicians can be linked to laboratory isolates, we concluded that most isolates have been captured from cultureconfirmed meningococcal disease cases in the province by the existing surveillance system. Only about 15% of the IMD cases were not included here, since they were diagnosed by PCR and therefore cultures were not available for further study.
The age distribution of cases due to isolates belonging to the serogroup B ST-269 clonal complex (CC) was compared to the age distribution of cases due to isolates belonging to other CCs by using the 2 test. Analyses were performed by using SAS software version 9.2 (SAS Institute, Cary, NC). A P value of Ͻ0.05 was considered statistically significant.
Identification, serogrouping, and typing of meningococci. N. meningitidis was identified by standard biochemical tests, and serogrouping was done by the bacterial agglutination test with rabbit serogrouping antisera at the LSPQ (42) . Serotyping and serosubtyping were done at the National Microbiology Laboratory (NML) using a whole-cell enzymelinked immunosorbent assay (ELISA) ( Multilocus sequence typing (MLST) was done according to the method described by Maiden et al. (34) , and isolates were assigned to STs according to the Neisseria MLST website (http://pubmlst.org/neisseria). Analysis of the MLST data from the ST-269 CC was done by eBURST (23) . Sequencing of porA genes was done following the protocols of Sacchi et al. (44) and Clarke et al. (12) . The PorA variable-region (VR) types were described according to the nomenclature given in the N. meningitidis PorA variable-region database (http://neisseria.org/perl/agdbnet/agdbnet .pl?fileϭporavr.xml) and by de Filippis et al. (13) . December 2010, a total of 466 culture-confirmed IMD cases were identified based on N. meningitidis isolates provided by the LSPQ to the NML, with an average of 58 cases per year. A retrospective audit of isolates at the two facilities found 95% to 100% agreement of the yearly data among the 466 case isolates identified over the 8-year period, and all invasive serogroup B isolates described in this report had been accounted for at both the LSPQ and the NML. Minor discrepancies included 2 case isolates from nonresidents of Québec, which were therefore not included in the LSPQ data set.
RESULTS

Serogroup distribution of invasive
However, these 2 isolates were received at the NML and were not excluded since it was not known at the time of our analysis if the individuals contracted their infection inside or outside Québec. Overall, 72% of the cases were due to serogroup B, while there were 75 cases (16%) caused by serogroup C, 29 cases (6%) caused by serogroup Y, 26 cases (5.6%) caused by serogroup W135, and 2 cases (0.4%) due to serogroup 29E ( Table 1) .
The number of serogroup B cases has been increasing since we first documented an outbreak in this province due to an emerging clone of ST-269 ( Clonal analysis of invasive serogroup B N. meningitidis isolates. A total of 89 sequence types (STs) were identified among the 334 invasive serogroup B isolates, and 75 of these 89 STs were grouped into 14 CCs, with the remaining 14 STs not assigned to any known CC according to the Neisseria MLST website ( Table 2 ). The genetic diversity of the different CCs may be examined by the number of STs involved in causing invasive disease. There was greater genetic diversity in the ST-41/44 CC strains than in the ST-269 CC strains responsible for IMD in the province of Québec in Canada.
Two CCs (ST-269 and ST-41/44) were responsible for 77% of all invasive serogroup B cases. The number of culture-positive IMD cases due to isolates within the ST-269 CC appeared to be increasing during the period of this study, from 10 cases in 2003 to 32 cases in 2010. This increase paralleled to the gradual increase in the percentage of invasive serogroup B cases due to this CC, from 35% in 2003 to 76% in 2010. In contrast, the number of cases due to isolates of the ST-41/44 CC appeared to be relatively stable throughout the study period, and this was also reflected in the cases caused by the ST-32 CC, 4 were due to ST-32, 3 were due to ST-2726, 2 were due to ST-33, and one case each was due to ST-2858 and ST-6544. The 6 case isolates that belonged to the ST-60 CC were highly related, with 4 isolates being ST-60 and the remaining 2 isolates being single-locus variants (SLVs) of ST-60, namely, ST-466 and ST-6546.
There were 3 cases due to the ST-11 or ET-37 CC. All 3 isolates were typed as B:2a:P1.7,1 and were of the ET-15 variant of the ST-11 or ET-37 CC.
Characteristics of the ST-269 clone in Québec, Canada. The distribution of isolates among the different STs in the ST-269 CC and their genetic relationship as revealed by the allelic profile of the multilocus sequence typing scheme are described in Fig. 1 . Of the 180 isolates that belonged to the ST-269 CC, 91.7% (165 iso- 
isolates).
Characteristics of culture-confirmed IMD cases due to isolates belonging to serogroup B ST-269 CC. In 115 cases (64%), the bacteria were isolated from cerebrospinal fluid (CSF) cultures of patients, including one case with the isolate obtained from both blood and CSF cultures. In contrast, 64 cases (36%) had positive blood cultures, and in one case the isolate was obtained from the synovial fluid. Although almost twice as many patients had positive CSF cultures than had positive blood cultures, the clinical presentations of the cases were not known, as this information is not routinely captured by our laboratory surveillance activities.
More than 50% of the cases occurred in those aged 11 to 40 years, with 55 cases (30.5%) among those aged 11 to 19 years and 46 cases (25.5%) in those aged 20 to 40 years. There were 30 cases (16.7%) in those aged 1 to 5 years, and 19 cases (10.6%) occurred in those aged 41 to 60 years. In contrast, there were only 9 cases (5%) in infants less than 12 months old, 9 cases (5%) in those aged 6 to 10 years, and only 12 cases (6.7%) in those over the age of 60 years. The age distribution of cases due to isolates belonging to serogroup B ST-269 CC was significantly different from those of cases due to isolates belonging to other CCs (P Ͻ 0.0001 by chisquare test) ( Table 4 ). There were almost twice as many cases in those aged 11 to 40 years due to the ST-269 CC (56%) compared to other CCs (30%). In contrast, there were almost 5 times fewer children Ͻ1year of age among cases due to the ST-269 CC (5%) compared to other CCs.
DISCUSSION
To the best of our knowledge, this study represents the largest single report of serogroup B IMD cases due to highly related isolates belonging to the ST-269 CC. In the past, epidemic spread of serogroup B strains involved clones or CCs such as ET-5 or ST-32 (e.g., in Norway in the mid-1970s with subsequent intercontinental spread [6] and more recently in the state of Oregon in the United States [20] ), ST-41/44 (e.g., in New Zealand beginning in 1991 [35] ), and ST-8 or cluster A4 (e.g., in The Netherlands in the 1960s [9] and in many European countries and North America in the1970s [7, 8] ). In the province of Québec, with a population of approximately 7.5 million in 2005 and 7.9 million in 2010 according to Statistics Canada, we have documented a total of 180 serogroup B IMD cases due to the ST-269 CC over the last 8 years. Ninety-two percent of the 180 cases were due to one single ST (ST-269), and 140 (85%) of the ST-269 isolates presented with the serotype and serosubtype antigens 17:P1.19 and PorA genotype VR1 19-1, VR2 15-11, VR3 36. This coupled with the fact that 30% of the cases were in those aged 11 to 19 years and another 26% in those aged 20 to 40 years all pointed toward a hyperendemic or epidemic spread of a single clone causing IMD in Québec (38) . Thus, the present findings suggest that this clone may indeed represent an emerging hypervirulent clone of meningococci. A detailed epidemiological analysis of this clone as well as other invasive serogroup B clones in Québec will be described separately in the near future.
Over P1.9 is a common antigen among serogroup B meningococci in Québec (data not shown). Based on multilocus sequence analysis, only 2 singleton isolates or 2 STs (ST-275 and ST-1163) were found among the 180 ST-269 CC isolates, which were distantly related to the parent clone of ST-269 (Fig. 1 ). Although these 2 isolates were also typed as B:17:P1.9, both had PorA genotypes of VR1 22, VR2 9, VR3 35-1. Also, both STs did not seem to have expanded and were not detected in subsequent years. The stability of the ST-269 clone in Québec during the past 8 years can be evidenced by a single predominant ST that represented 92% of all the isolates found in this CC, suggesting limited diversification or mutations in their housekeeping enzyme genes. Other single-or double-locus variants of the ST-269 clone also were restricted mostly to causing single cases, other than ST-1986, which caused a total of 6 cases over the years. Also, most (83%) of the ST-269 CC isolates detected in this province had the antigens B:17:P1.19 with a PorA genotype of VR1 19-1, VR2 15-11, VR3 36. Stability of the PorA antigen and genotype during a meningococcal disease epidemic in New Zealand over a period of 13 years has also been reported (16) . However, upon intercontinental spread, diversifications do appear to occur, as has been reported for the ET-5 (5) and ET-15 (30) clones. This is most likely the result of genetic recombinations occurring between the epidemic clone and endemic meningococci unique to the locality.
According years. However, it is interesting to note that the ST-275 isolate and its SLV of ST-1163 found in Québec also had the PorA genotype of VR1 22, VR2 9, similar to that found in England and Wales (33) .
Besides the cases that we had documented in Québec, Canada, 2 other smaller clusters or outbreaks of IMD cases due to the ST-269 CC have been described in the literature. Invasive serogroup B isolates that belong to the ST-269 CC are not very common in other Canadian provinces, with only about 50 such isolates identified in the past 8 years. Also, no particular ST appears to predominate, and as many as 14 distinct STs have been identified from Canadian provinces other than Québec (unpublished data from the NML).
In the United States, among the 520 serogroup B isolates analyzed from the period from 1 January 2000 to 31 December 2005, only 20 isolates, or 3.8%, belonged to the ST-269 CC. Heterogeneity of the ST-269 CC was reflected by 15 distinct STs being represented among the 20 isolates analyzed, with no single predominant ST found (27) . In Asia, ST-269 was either rare or not described at all in the 3 studies reported from that region, namely, from China (55), Japan (47), and Taiwan (11) .
In contrast to the ST-269 CC with very limited heterogeneity, invasive serogroup B isolates in Québec that belonged to the ST-41/44 CC were much more diverse genetically. (27) . Similarly, ST-571 was either absent or infrequent among the ST-41/44 CC isolates analyzed in a study involving isolates from the Czech Republic, Greece, and Norway (56) .
Two candidate serogroup B meningococcal vaccines are in advanced stages of development. The 4CMenB investigational vaccine contains four components: factor H binding protein (fHBP), neisserial heparin binding antigen (NHBA), neisserial adhesin A (NadA), and the PorA antigen P1.4 (25) . The other investigational MenB vaccine is a bivalent fHBP (39) . Therefore, our next goal will be to examine the genetic and antigenic diversity of the multiple investigational vaccine antigens among our collection of invasive serogroup B isolates. A small pilot study involving DNA sequencing of the antigen genes in a dozen ST-269 isolates recovered from 2003 to 2010 has indicated the absence of NadA and P1.4 and the presence of fHBP allele 15 (or Novartis variant 1 subvariant 15) and NHBA subvariant 21 (data not shown). This is similar to the type of 4CMenB vaccine antigens found among invasive serogroup B ST-269 isolates collected from England and Wales (33) .
Since the Québec ST-269 CC isolates did not express the PorA P1.4 or the NadA antigen present in the 4CMenB investigation vaccine, the effectiveness of this candidate vaccine against the ST-269 CC isolates will depend solely on (i) how well the vaccine components fHBP and NHBA will match with the corresponding antigens found in the clinical isolates and (ii) how well these antigens are expressed in vivo by the clinical isolates. Since a significant proportion of the ST-269 CC cases in Québec were due to one homogenous clone of defined PorA antigens, with 94% of the strains possessing the PorA VR2 type 19-11 or 9 (Table 3) , it may be feasible to develop a bivalent PorA vaccine that will be ST-269 specific for use in the province of Québec. An advantage of a PorA-specific vaccine is its proven track record in effectiveness against a homogeneous population of meningococci expressing homologous PorA antigens (4, 15, 37, 45) . However, vaccines with narrow specificities that target only one or a limited number of serogroups or serotypes, such as the capsular polysaccharide vaccines, in meningococci or pneumococci have a high propensity to lead to the development of vaccine escape mutants due to the phenomenon of capsule switching (52) or capsule replacement (51) and even phase variation in antigen expression (26) . Unfortunately, in N. meningitidis, a single species-specific virulence factor that would allow development of an effective vaccine, such as the diphtheria or tetanus toxoid, has not been identified. In search of a comprehensive vaccine against serogroup B meningococci, some investigators have proposed that multiple components may enhance the effectiveness of the vaccine coverage and at the same time minimize the possibility of engendering vaccine escape mutants (21) . However, this theory has not been proven in a realworld situation, and therefore further studies involving the epidemiology and laboratory characterization of strains, as well as the postmarketing of any such vaccines, are now required.
